Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun 1;175(6):631-632.
doi: 10.1001/jamapediatrics.2020.6150.

Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial

Pietro Ravani  1 , Francesca Lugani  2 , Stefania Drovandi  2 , Gianluca Caridi  3 , Andrea Angeletti  2 , Gian Marco Ghiggeri  2
Affiliations
Randomized Controlled Trial

Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial

Pietro Ravani et al. JAMA Pediatr. .

Abstract

This randomized clinical trial examines the superiority of a single dose of rituximab vs low-dose mycophenolate mofetil in preventing the recurrence of steroid-dependent nephrotic syndrome in children and young adults.

Trial registration: ClinicalTrials.gov NCT04402580.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ghiggeri reported grants from Italian Ministry of Health No Profit grant (Ricerca Finalizzata PE-2016-02361576) during the conduct of the study. No other disclosures were reported

Figures

Figure 1.
Figure 1.. Schematic View of Trial Design
MMF indicates mycophenolate mofetil; PDN, prednisone.
Figure 2.
Figure 2.. One-Year Relapse-Free Survival in the Rituximab and Mycophenolate Mofetil (MMF) Arms
The risk of relapse was 0.8 (12/15) in the MMF and 0.13 (2/15; P = .008 in the rituximab arm, with higher odds in the MMF arm (odds ratio, 26; 95% CI, 2.9-311.0).
See this image and copyright information in PMC

Comment in

References

    1. Ravani P, Rossi R, Bonanni A, et al. . Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259-2266. doi:10.1681/ASN.2014080799 - DOI - PMC - PubMed
    1. Ravani P, Lugani F, Pisani I, et al. . Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol. 2020;35(8):1437-1444. doi:10.1007/s00467-020-04540-4 - DOI - PubMed
    1. Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U; Gesellschaft für Pädiatrische Nephrologie (GPN) . Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689-1697. doi:10.1681/ASN.2012121200 - DOI - PMC - PubMed
    1. Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20(9):1265-1268. doi:10.1007/s00467-005-1957-y - DOI - PubMed
    1. Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol. 2005;20(10):1376-1381. doi:10.1007/s00467-005-1964-z - DOI - PubMed

Publication types

Associated data